Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Gilead Sciences, Inc.
  6. Consensus
    GILD   US3755581036

GILEAD SCIENCES, INC.

(GILD)
  Report
Delayed Nasdaq  -  05/17 04:00:00 pm EDT
63.18 USD   +1.51%
04:31pGilead and Kite Oncology to Highlight Advances Supporting New Innovations in Cancer Care at the ASCO Annual Meeting
BU
11:01aGilead Sciences, Inc. - FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention of HIV
AQ
10:29aWALL STREET STOCK EXCHANGE : Finding the tipping point
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Evolution of the average Target Price on GILEAD SCIENCES, INC.
Target Price consensus revisions : last 18 months
Recommendations (Chart) GILEAD SCIENCES, INC.
Analyst Recommendations on GILEAD SCIENCES, INC.
06:08aANALYST RECOMMENDATIONS : AMD, CarMax, Gilead, J.B. Hunt, Vodafone...
05:09aPiper Sandler Adjusts Gilead Sciences' Price Target to $69 From $73, Maintains Neutral Rat..
MT
05/13UBS Adjusts Gilead Sciences Price Target to $64 From $65, Maintains Neutral Rating
MT
04/29BMO Capital Adjusts Gilead Sciences Price Target to $63 From $65, Maintains Market Perform..
MT
04/29Piper Sandler Adjusts Gilead Sciences' Price Target to $73 From $72, Maintains Neutral Rat..
MT
04/12Morgan Stanley Lowers Gilead Sciences Price Target to $63 From $69, Maintains Euqalweight ..
MT
04/12RBC Raises Price Target on Gilead Sciences to $77 From $76 as FDA Lifts Partial Clinical H..
MT
More recommendations
Analysis
GSK to buy Sierra Oncology amid pressure to boost drug pipeline
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 63,18 $
Average target price 70,07 $
Spread / Average Target 10,9%
High Price Target 90,00 $
Spread / Highest target 42,5%
Low Price Target 56,00 $
Spread / Lowest Target -11,4%
Consensus detail
Consensus revision (last 18 months)